๐๐ง๐ฉ๐๐๐ค๐ข๐ง๐ ๐&๐โ๐ฌ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐๐จ๐๐๐ฅ
Historically, Johnson & Johnson reported its revenue under three main divisions, namely: Pharma, MedTech, and Consumer. In 2023, J&J spun off its Consumer division under the brand Kenvue, while retaining the other two divisions.
Today, under CEO Joaquin Duato, Johnson & Johnson positions itself not just as a โMedTechโ or โPharmaโ, but as a broader โHealthcareโ company, generating $89B in annual revenue with the following breakdown:
1- Innovative Medicine (Pharma) (64%),
2- MedTech (36%).
Led by Jennifer Taubert, the Johnson & Johnson Innovative Medicine division generates $57B in annual revenue, with the following breakdown:
- Oncology (36%),
- Immunology (31%),
- Neuroscience (12%),
- Pulmonary Hypertension (8%),
- Infectious Diseases (6%),
- Cardiovascular/Metabolism/Other (6%).
Led by Tim Schmid, the Johnson & Johnson MedTech division generates $32B in annual revenue, with the following breakdown:
- Surgery (31%),
- Orthopedics (29%),
- Cardiovascular (24%),
- Vision (16%).
Get Reza Zahiriโs stories inย yourย inbox
Join Medium for free to get updates fromย thisย writer.
Johnson & Johnson is a unique company with two exceptionally mature divisions, each employing more than 60,000 people. A split would instantly make J&Jโs MedTech business the worldโs second-largest medical device company by revenue. At the same time, its pharmaceutical arm would likewise become the second-largest pharma company overnight. It would be interesting to see whether J&J chooses to pursue this path in the coming years or will continue to keep both businesses under the same umbrella.
Views are my own. Content is all public data intended to be educational and not financial advice. I encourage readers to do their research โ visualization by PlotSet.
